A language delay is a language disorder in which a child fails to develop language abilities at the usual age-appropriate period in their developmental timetable. It particularly affects deaf children who are denied sign language. It is most commonly seen in children ages two to seven years-old and can continue into adulthood. The reported prevalence of language delay ranges from 2.3 to 19 percent.Language is a uniquely human form of communication that entails the use of words in a standard and structured way. Language is distinct from communication. Communication is a two-stage process. The first stage is the process of encoding the message into a set of words (or signs in the case of Sign Languages) and sentence structures that convey the required meaning, i.e. into language. In the second stage, language is translated into motor commands that control the articulators (hands, face, body, lungs, vocal cords, mouth, tongue, teeth, etc. ), thereby creating speech. Language delays are distinct from speech delays, in which the development of the mechanical and motor aspects of speech production are delayed. Many tend to confuse language delay with speech delay or even just late talker. All of these have different telltale signs and determining factors. Speech delay seems to be more similar to late talker compared to language delay. Speech is the verbal motor production of language, while language is a means of communication. Because language and speech are independent, they may be individually delayed.
Side effects
Side effects of PPIs in general and lansoprazole in particular may include:
Common: diarrhea, abdominal pain
Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions including (erythroderma, Stevens–Johnson syndrome, toxic epidermal necrolysis, bullous eruption)PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea. : 22

Interactions
Lansoprazole interacts with several other drugs, either due to its own nature or as a PPI. PPIs reduce absorption of antifungals (itraconazole and ketoconazole)  and possibly increase digoxin in plasma
Increases plasma concentrations of cilostazol (risk of toxicity)Lansoprazole possibly interacts with, among other drugs:

sucralfate
ampicillin
bisacodyl
clopidogrel
delavirdine
fluvoxamine
iron salts
voriconazole
aminophylline and theophylline
astemizole

Chemistry
It is a racemic 1:1 mixture of the enantiomers dexlansoprazole and levolansoprazole. Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift. Lansoprazoles plasma elimination half-life (1.5 h) is not proportional to the duration of the drugs effects to the person (i.e. gastric acid suppression). History
Lansoprazole was originally synthesized at Takeda and was given the development name AG 1749. Takeda patented it in 1984 and the drug launched in 1991. In the United States, it was approved for medical use in 1995. Society and culture
Patents
The lansoprazole molecule is off-patent and so generic drugs are available under many brand names in many countries; there are patents covering some formulations in effect as of 2015. Patent protection expired on 10 November 2009.